Stock Taper
EARNINGS CALL ARCHIVE 1 CALL ON FILE
IBRX — ImmunityBio, Inc.
NASDAQ
FULL STOCK PAGE →

Q4 2025 Earnings Call Summary

MAR 3, 2026
REVENUE
$38.3M +19.4%
NET MARGIN
-161.8% +48.0 PTS
EPS
-$0.06 +11.8%
FREE CASH FLOW
-$71.7M -2.8%

No summary has been written for this call yet.